KPTI Karyopharm Therapeutics Inc. stock chart & analysis
Conviction 40HealthcareScan · Wed, Oct 28, 2026Karyopharm Therapeutics Inc. (KPTI) closed at $0.8323 (+73.40%) on Oct 28, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 49, RS Rating 7, -92.4% from its 52-week high, -88.7% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Price chart, 63 bars from Fri, Jul 31, 2026 to Wed, Oct 28, 2026. Last close $0.8323, high $2.43, low $0.3100.
Why KPTI moved
From the StockSetups movers recaps that covered KPTI, newest first. A recap states what was known that day.
- Close+73.4%
Karyopharm surged 73.4% to close at $0.83 on 32.6 million shares. That is roughly ten times its 20-day average of about 3.4 million. The market cap is only $10.7M, so this is a micro-cap.
Top Stock Movers Oct 28, 2026: Why KPTI, FTFT, PODC Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
KPTI technical analysis
Trend
KPTI is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 34.3% below the 50-day ($1.27) and 86.4% below the 200-day ($6.10). ADX(14) at 54 points to a strong, established trend. It meets 1 of 8 trend-template criteria.
Momentum
RSI(14) is 49, in the bearish half of its range. MACD crossed above its signal line 7 sessions ago. Its RS Rating of 7 puts its weighted 12-month performance ahead of about 7% of the US market.
Volume and volatility
Volume on the latest session ran 17.7× its 20-day average. It trades about $2.3M a day on average. ATR(14) is $0.1448, 17.4% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.37) shows accumulation.
Key levels
The chart pattern's support is $0.7750 and its resistance $1.24. The 52-week range is $0.3100 to $10.99; price is 92.4% below the high and 168.5% above the low. The VWAP anchored at the 52-week high is $3.61, above price.
Performance
KPTI returned +96.1% (1 week), -30.9% (1 month), -88.1% (3 months), -90.1% (6 months), -87.0% (1 year), -88.7% (year to date).
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Pharmaceutical Preparations · Listed 2013 · 228 employees
Recent news
- Four reporting parties each list the same stake in Karyopharm (KPTI).Stock Titan · Wed, Oct 28, 2026
- Karyopharm schedules November 2 results for Karyopharm stockad-hoc-news.de · Tue, Oct 27, 2026
- Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & UpdatesKalkine · Mon, Oct 26, 2026
- Karyopharm Therapeutics stock sits 95.48 percent below targetad-hoc-news.de · Sat, Oct 24, 2026
Insider activity
SEC Form 4 transactions in KPTI · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Abate Kristin Chief Accounting Officer · Common Stock · 2026-10-16 | Sell | 4.79K | $2K | 2026-10-16 | 2026-10-19 |
Abate Kristin Chief Accounting Officer · Common Stock · 2026-10-01 | Sell | 378 | $450 | 2026-10-01 | 2026-10-02 |
Abate Kristin Chief Accounting Officer · Common Stock · 2026-09-01 | Sell | 19 | $38 | 2026-09-01 | 2026-09-02 |
PAKIANATHAN DEEPIKA Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
Su Zhen Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
Schor Chen Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
Greene Barry E Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
Oliger Christy J. Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
BOHLIN GAREN G Director · Common Stock · 2026-05-21 | Grant | 15.51K | $0 | 2026-05-21 | 2026-05-26 |
Paulson Richard A. President and CEO · Common Stock · 2026-05-14 | Sell | 2.2K | $21K | 2026-05-14 | 2026-05-15 |
SEC filings
EDGAR filings in KPTI · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.